How to Get Leqvio (Inclisiran) in Arizona

What Is Leqvio and Why Arizona Patients Are Seeking It

Leqvio is a small-interfering RNA (siRNA) that silences PCSK9 synthesis in the liver, reducing circulating LDL-C by roughly 50% with only two injections per year after the loading phase. The FDA approved inclisiran on December 22, 2021, for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) whose LDL-C remains above goal despite maximally tolerated statin therapy. You can review the full prescribing information at the FDA label page.

The key ORION-10 trial (N=1,561) enrolled patients with ASCVD and demonstrated that inclisiran 284 mg reduced LDL-C by 52.3% from baseline at day 510 compared with placebo (P<0.001). [1] The companion ORION-11 trial (N=1,617) replicated those results across patients with HeFH or high cardiovascular risk, showing a 49.9% LDL-C reduction versus placebo at day 510 (P<0.001). [1] Both trials were published in the New England Journal of Medicine in 2020. The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol designates PCSK9 inhibition as a Class IIa recommendation for very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on high-intensity statin plus ezetimibe. [2]

Arizona has over 7.4 million residents, and the CDC estimates that heart disease remains the leading cause of death in the state, accounting for roughly 1 in 4 deaths nationally. [3] That disease burden means a meaningful number of Arizonans qualify for PCSK9 inhibition yet remain undertreated.

Who Qualifies for a Leqvio Prescription in Arizona

Qualification depends on two intersecting criteria: the FDA-approved indication and the payer's prior authorization requirements.

The FDA label limits inclisiran to adults with HeFH or clinical ASCVD (prior MI, stroke, or symptomatic peripheral artery disease) who need additional LDL-C lowering. [4] In practice, most Arizona commercial payers also require documentation that the patient has been on a high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) for at least 90 days, with an LDL-C that remains at or above 70 mg/dL for ASCVD patients or 100 mg/dL for HeFH patients without ASCVD.

The American College of Cardiology's 2022 Expert Consensus Decision Pathway states: "For patients with very-high-risk ASCVD who are on maximally tolerated LDL-C-lowering therapy, including statin and ezetimibe, and who have LDL-C >70 mg/dL, PCSK9 inhibitors are recommended." [2] That language maps directly onto Leqvio's approved population and guides how Arizona prescribers document medical necessity.

Patients with homozygous FH (HoFH) are not in the current FDA label for inclisiran. Statin-intolerant patients may still qualify if they have documented adverse effects from at least two statins at the lowest available doses, which is a separate pathway that most Arizona payers will accept with adequate medical records. [5]

How to Find a Leqvio Prescriber in Arizona

Arizona allows telehealth prescribing of Leqvio. No in-person visit is required by state statute, provided the prescriber establishes a valid patient-provider relationship and reviews sufficient clinical data. The Arizona Telemedicine Act (A.R.S. § 36-3601 et seq.) permits synchronous video consultations to satisfy this requirement.

Qualified prescribers include MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) practicing within their scope. Arizona NPs with full practice authority can independently prescribe Leqvio. PAs must have a supervising or collaborating physician on record per Arizona Revised Statutes Title 32. Either credential is sufficient for the payer's prior authorization; insurers do not typically require a cardiologist signature, though some Medicare Advantage plans request specialist attestation.

Cardiologists and lipidologists remain the most common prescribers because they manage the underlying ASCVD or FH diagnosis. Internal medicine and family medicine physicians represent the second-largest group. Telehealth platforms that operate under Arizona licensure can initiate a prescription after a video visit, but the injection itself must be administered by a licensed healthcare professional. Leqvio is not a self-injectable product; the FDA label specifies administration by a healthcare provider. [4]

HealthRX connects Arizona patients with licensed prescribers for an initial telehealth evaluation. After the evaluation, the prescriber submits the prior authorization to your insurer and coordinates with a specialty pharmacy for delivery to your injecting provider.

Required Labs and Clinical Documentation

A fasting lipid panel is the minimum lab requirement before any Leqvio prescription is written. Ideally the panel was drawn within 90 days. The relevant values are total cholesterol, LDL-C (calculated or direct), HDL-C, non-HDL-C, and triglycerides.

Beyond lipids, prescribers need:

• Documentation of current or prior statin therapy (drug name, dose, duration)
• Evidence of the qualifying diagnosis (catheterization report, imaging confirming ASCVD, or genetic testing/clinical criteria for FH)
• A list of current cardiac medications (ezetimibe, bile acid sequestrants, bempedoic acid)
• Liver function tests if liver disease is suspected, because inclisiran is metabolized hepatically [4]

The PCSK9 Inhibitor Payer Criteria published through the American Heart Association outlines that most commercial payers require at least two LDL-C values above the threshold, measured at least 4 weeks apart, to rule out transient elevation. [6] Collecting a second lipid panel before your telehealth appointment can shorten the prior authorization timeline by one to three weeks.

Inclisiran does not require routine renal dose adjustment for mild-to-moderate chronic kidney disease, but patients with severe renal impairment (eGFR <30 mL/min/1.73m²) were underrepresented in the ORION trials, and the FDA label notes limited data in that population. [4] An eGFR from a recent basic metabolic panel is a reasonable precaution.

The Prior Authorization Process for Arizona Payers

Prior authorization (PA) is the single largest obstacle Arizona patients face. Most commercial plans in Arizona, including Blue Cross Blue Shield of Arizona, UnitedHealthcare, Aetna, and Cigna, require PA before dispensing inclisiran.

The standard PA packet includes:

1. The signed prescription from a licensed AZ provider
2. A letter of medical necessity explaining the qualifying diagnosis, statin history, and current LDL-C
3. Copies of the relevant lipid panels (two measurements preferred)
4. Documentation of statin plus ezetimibe trial, or statin-intolerance records
5. ICD-10 codes (I25.10 for ASCVD, E78.01 for HeFH, or Z82.49 for family history with FH criteria)

Initial PA decisions typically arrive within 3 to 10 business days for commercial plans. If the first PA is denied, Arizona insurers are required under A.R.S. § 20-2537 to provide a written denial reason and to allow an appeal. An expedited appeal can be requested when a prescriber certifies that the delay poses a risk to the patient's health.

The ACC's guidance on prior authorization burdens notes that PA for PCSK9 inhibitors takes an average of 16 hours of administrative time per approval. [7] Specialty pharmacies familiar with inclisiran, including those contracted through Novartis's Leqvio360 patient support program, can handle much of that burden on the prescriber's behalf.

Arizona Medicaid (AHCCCS) does not routinely cover Leqvio as of mid-2025. Patients on AHCCCS should ask their prescriber about the Novartis patient assistance program, which provides inclisiran at no cost to patients who meet income eligibility criteria. The eligibility threshold is typically at or below 400% of the federal poverty level.

How Leqvio Is Dispensed and Administered in Arizona

Inclisiran is classified as a specialty biologic and is dispensed exclusively through specialty pharmacies. It is not stocked at retail pharmacies such as CVS or Walgreens. The two main distribution channels in Arizona are:

Specialty pharmacy ship-to-clinic: The pharmacy ships the prefilled syringe (284 mg/1.5 mL) directly to your prescribing clinic or infusion center. The product must be stored at 20-25°C and is stable for up to 24 months. The clinic administers the injection subcutaneously in the abdomen, upper arm, or thigh.

Specialty pharmacy with in-office buy-and-bill: Some Arizona cardiology practices purchase inclisiran directly through a specialty distributor and bill insurance under the medical benefit rather than the pharmacy benefit. This route can reduce out-of-pocket costs for patients with strong medical-benefit coverage.

Arizona does not have a specific law prohibiting 503A compounding pharmacies from preparing inclisiran, but FDA guidance on compounding of approved drugs establishes that compounding a commercially available drug like Leqvio requires individualized patient need justification. [8] The purity and potency of compounded siRNA molecules present significant pharmaceutical challenges, and no 503A pharmacy in Arizona is known to have an active PCSK9 siRNA compounding program as of this writing.

Timeline: From First Telehealth Visit to First Injection

Arizona patients consistently ask how long the process takes. A realistic breakdown:

• Day 1: Telehealth visit with a licensed AZ prescriber. Prescription sent to specialty pharmacy. PA packet submitted to insurer.
• Days 3-10: Insurer renders PA decision (commercial plans). Medicare Part D plans may take up to 14 days.
• Days 11-15: Specialty pharmacy verifies PA approval, contacts patient for copay card enrollment, and ships product to clinic.
• Days 15-20: Clinic schedules injection appointment. First injection administered.

The realistic minimum is about 15 business days from first visit to first injection when the PA is approved on the first attempt. Delays in collecting medical records are the most common reason timelines extend beyond 30 days.

After the initial injection on day 1, a second injection is given at month 3 (the loading dose), and then every 6 months thereafter. Missing a dose by up to 3 months does not require restarting the series, according to the FDA label. [4]

Leqvio Cost and Patient Assistance in Arizona

The wholesale acquisition cost of Leqvio is approximately $3,500 per injection, or roughly $7,000 per year for the two maintenance doses. With prior authorization and commercial insurance, patient out-of-pocket cost varies widely.

Novartis offers the Leqvio360 copay assistance program for commercially insured patients, which can reduce out-of-pocket cost to as low as $0 per injection for eligible patients. Enrollment requires a valid prescription and proof of commercial insurance. Medicare and Medicaid patients do not qualify for manufacturer copay cards under federal anti-kickback statutes, but the Novartis patient assistance program (PAP) covers uninsured or underinsured patients who meet income criteria. [9]

The ACC/AHA Cholesterol Guideline explicitly acknowledges cost as a barrier to PCSK9 inhibitor access, stating: "Cost-effectiveness analyses suggest that PCSK9 inhibitors provide acceptable value at prices well below their current list prices." [10] Price reductions negotiated through pharmacy benefit managers have brought effective net prices closer to $2,000-$2,500 per injection in some Arizona plan formularies, improving access incrementally since 2022.

The HealthRX Arizona Access Framework for Leqvio outlines three patient tracks based on insurance status. Track 1 covers commercially insured patients with ASCVD or HeFH who initiate PA through a telehealth visit and use the Novartis copay card. Track 2 covers Medicare patients who require a specialist letter and appeal preparation given formulary step-therapy requirements common in Arizona Medicare Advantage plans. Track 3 covers uninsured or AHCCCS patients who apply to the Novartis PAP before the telehealth visit to confirm eligibility, avoiding a prescribing delay.

Transferring a Leqvio Prescription to Arizona

Patients who began inclisiran in another state and relocated to Arizona face a practical gap: the original prescriber is out of state and Leqvio requires ongoing specialty pharmacy coordination. Arizona does not recognize out-of-state prescriptions for specialty injectables in the same way retail prescriptions transfer under chain pharmacy systems.

The correct process is: obtain a new prescription from an Arizona-licensed provider. That provider reviews your existing treatment records, confirms your LDL-C response (a follow-up lipid panel drawn 90 days after your last injection is standard), and resubmits PA to your current Arizona insurer. Your injection schedule does not reset if the gap between doses is under 9 months (three months beyond the planned 6-month interval). [4]

Bring the following to your Arizona transition visit: your complete lipid panel history since starting inclisiran, the dates of all prior injections, your current statin prescription, and the contact information for the specialty pharmacy that previously supplied your medication. Most Arizona telehealth platforms can complete this transition visit within one business day.

Monitoring LDL-C Response in Arizona

Inclisiran's maximal LDL-C lowering effect is visible by day 90 after each injection. The ORION-10 and ORION-11 trials used a treat-to-target approach anchored to an LDL-C below 70 mg/dL for ASCVD patients, a threshold endorsed by the 2019 ESC/EAS Guidelines for Dyslipidaemia. [11] Arizona providers following ACC/AHA guidelines target LDL-C below 70 mg/dL for very-high-risk ASCVD and below 55 mg/dL for patients with two or more major ASCVD events. [2]

A fasting lipid panel at the 3-month follow-up visit (timed with the loading-dose injection) efficiently confirms response and generates the data needed for PA renewal. Most Arizona commercial insurers require annual PA renewal for inclisiran, which necessitates an updated lipid panel and a brief provider attestation that the patient continues to meet the original eligibility criteria.

Liver enzyme monitoring is not mandated by the FDA label for inclisiran, which differentiates it from statins. [4] Injection-site reactions occurred in 2.6% of inclisiran-treated patients versus 1.8% of placebo patients in pooled ORION data, and were predominantly mild. [1] Patients should notify their Arizona provider if they notice persistent redness, induration, or pain at the injection site lasting more than 72 hours.

The American Association of Clinical Endocrinology 2022 Consensus Statement on Dyslipidemia recommends repeat lipid testing at 6-12 weeks after any new lipid-lowering agent is added, a guideline directly applicable to the 3-month Leqvio loading-dose visit in Arizona clinical practice. [12]